ESLA Stock Forecast: Estrella Immunopharma, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 26 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Estrella Immunopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (83): Reported profit is backed by cash, and the company is not expanding recklessly.
Quality (12): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ESLA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ESLA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Feb 2026 | D. Boral Capital | Maintains | Buy | $8.00 |
| 28 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 3 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 12 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 3 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 29 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 21 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 18 Feb 2025 | D. Boral Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
ESLA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ESLA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Estrella Immunopharma, Inc. returned −79.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ESLA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −251.9%
- Dividend yield
- —
Higher than 1% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Estrella Immunopharma, Inc. has a market value of $14.6M and an enterprise value of $16.4M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$10.0M.
Free cash flow in the twelve months to 30 June 2026: −$9.4M.
Estrella Immunopharma, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.
Data provided by Twelve Data
ESLA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ESLA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Estrella Immunopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ESLA
How does Ticker Nerd's model rank ESLA?
As at 21 Nov 2026, Estrella Immunopharma, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (83 of 100).
What is the ESLA stock forecast for 2030?
No analyst covering Estrella Immunopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ESLA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.
How has ESLA stock performed over the past year?
Estrella Immunopharma, Inc. returned -79.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Estrella Immunopharma, Inc. do?
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing T-cell therapies for blood cancers, solid tumors, and certain autoimmune diseases. The company is centered on CD19- and CD22-targeted ARTEMIS T-cell programs designed to harness the immune system’s ability to recognize and attack diseased cells.
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing T-cell therapies for blood cancers, solid tumors, and certain autoimmune diseases. The company is centered on CD19- and CD22-targeted ARTEMIS T-cell programs designed to harness the immune system’s ability to recognize and attack diseased cells. Its current pipeline includes EB103 and EB104 for B-cell malignancies, along with EB201, which is being explored for systemic lupus erythematosus. Estrella Immunopharma operates in the advanced immunotherapy and cell therapy segment of the biopharmaceutical market, where it aims to address treatment challenges through engineered immune-based approaches. Headquartered in Emeryville, California, Estrella Immunopharma is positioned as a research-driven company developing next-generation therapies for oncology and autoimmune disorders.
CEO Ms. Cynthia Pussinen · United States · https://www.estrellabio.com